Local News

• Nexavar significantly extends overall survival in liver cancer by 47 percent  Bayer HealthCare and Onyx Pharmaceuticals announced that Nexavar(R) tablets significantly improved overall survival by 47.3 percent in patients in the Asia-Pacific region with advanced hepatocellular carcinoma, or primary liver cancer, versus those receiving placebo.
  Bayer May 16, 2008  
• ADVENTRX announces ANX-530 safety data from registrational bioequivalence clinical study  ADVENTRX Pharmaceuticals announced that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general disorders and administration site conditions when compared to Navelbine(R).
  ADVENTRX Pharmaceuticals, Inc. May 16, 2008  
• Dynavax TOLAMBA(TM) chamber study misses primary endpoint  Dynavax reported primary endpoint data from a chamber study of TOLAMBA(TM) that showed a measurable clinical benefit, reducing total nasal symptom score by 41% vs. placebo in 253 patients in the intent-to-treat population and by 51% vs. placebo in 222 patients in the per-protocol population.
  Dynavax Technologies Corporation May 16, 2008  
• Invitrogen launches cell therapy business unit  Invitrogen announced its further commitment to advancing the clinical cell therapy field by creating a new business unit within the company focused on the specific needs of that market.
  Invitrogen Corporation May 16, 2008  
• Respirators for general public use in public health medical emergencies now available  Consumers concerned about an influenza outbreak can breathe a little easier: 3M has just released two new NIOSH N95 respirators for use by the general public in public health medical emergencies.
  3M May 16, 2008  
• Scientists in Spain develop new methods for monitoring drug abuse  Scientists at the Spanish Council for Scientific Research in Barcelona have developed a new method for monitoring the consumption of drugs of abuse in the general population. This method was was developed using analytical laboratory technology from Applied Biosystems/MDS Analytical Technologies.
  Applied Biosystems May 15, 2008  
• IDM Pharma announces updated data from mifamurtide compassionate access program  IDM Pharma announced the presentation of updated data from a compassionate access program evaluating mifamurtide (L-MTP-PE) in patients with lung metastases as a result of the progression of osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
  IDM Pharma, Inc. May 15, 2008  
• VIA Pharmaceuticals completes enrollment in Phase 2 Acute Coronary Syndrome (ACS) trial  VIA Pharmaceuticals announced that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one of three Phase 2 trials investigating VIA-2291, the company's lead product candidate in cardiovascular disease.
  VIA Pharmaceuticals, Inc. May 15, 2008  
• Wyeth's major depressive disorder treatment Pristiq now available in U.S. pharmacies  Wyeth Pharmaceuticals announced that PRISTIQ(TM), a new serotonin-norepinephrine reuptake inhibitor approved to treat adult patients with major depressive disorder, is now available in U.S. retail pharmacies nationwide. The recommended dose of PRISTIQ is 50 milligrams (mg) once daily.
  Wyeth May 15, 2008  
• ASCO study confirms importance of histology in treatment of non-small cell lung cancer  Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer clinical trial.
  Eli Lilly and Company May 15, 2008  

   (next 10 articles)